Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279 in AML
NCT03412292Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Aug 2018
- Primary completion
- Nov 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nefextinib in acute myeloid leukemia (AML), sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Adverse events (AEs) at 8 weeks and Maximum tolerated dose at 4 weeks. Status: unknown.
02
Drugs
nefextinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03412292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412292.